Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma.
biomarkers
diffusion
glioblastoma
magnetic resonance imaging
radiomics
treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
23
01
2023
revised:
19
04
2023
accepted:
24
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Glioblastoma often recurs after treatment. Bevacizumab increases progression-free survival in some patients with recurrent glioblastoma. Identifying pretreatment predictors of survival can help clinical decision making. Magnetic resonance texture analysis (MRTA) quantifies macroscopic tissue heterogeneity indirectly linked to microscopic tissue properties. We investigated the usefulness of MRTA in predicting survival in patients with recurrent glioblastoma treated with bevacizumab. We evaluated retrospective longitudinal data from 33 patients (20 men; mean age 56 ± 13 years) who received bevacizumab on the first recurrence of glioblastoma. Volumes of contrast-enhancing lesions segmented on postcontrast T1-weighted sequences were co-registered on apparent diffusion coefficient maps to extract 107 radiomic features. To assess the performance of textural parameters in predicting progression-free survival and overall survival, we used receiver operating characteristic curves, univariate and multivariate regression analysis, and Kaplan-Meier plots. Longer progression-free survival (>6 months) and overall survival (>1 year) were associated with lower values of major axis length (MAL), a lower maximum 2D diameter row (m2Ddr), and higher skewness values. Longer progression-free survival was also associated with higher kurtosis, and longer overall survival with higher elongation values. The model combining MAL, m2Ddr, and skewness best predicted progression-free survival at 6 months (AUC 0.886, 100% sensitivity, 77.8% specificity, 50% PPV, 100% NPV), and the model combining m2Ddr, elongation, and skewness best predicted overall survival (AUC 0.895, 83.3% sensitivity, 85.2% specificity, 55.6% PPV, 95.8% NPV). Our preliminary analyses suggest that in patients with recurrent glioblastoma pretreatment, MRTA helps to predict survival after bevacizumab treatment.
Identifiants
pubmed: 37296988
pii: cancers15113026
doi: 10.3390/cancers15113026
pmc: PMC10252262
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Genes (Basel). 2022 Jun 13;13(6):
pubmed: 35741816
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
J Neurooncol. 2010 Feb;96(3):423-31
pubmed: 19859666
J Neurooncol. 2011 Mar;102(1):95-103
pubmed: 20798977
Neurooncol Adv. 2021 Jun 19;3(1):vdab082
pubmed: 34377989
Sci Rep. 2019 Oct 8;9(1):14435
pubmed: 31594994
Front Oncol. 2021 Feb 05;10:574012
pubmed: 33614476
J Clin Oncol. 2011 Jan 10;29(2):142-8
pubmed: 21135282
AJNR Am J Neuroradiol. 2011 May;32(5):882-9
pubmed: 21330401
Med Oncol. 2019 Nov 11;37(1):2
pubmed: 31713115
Cancer. 2020 Jun 1;126(11):2625-2636
pubmed: 32129893
J Neurooncol. 2009 Oct;95(1):1-11
pubmed: 19381441
Neuro Oncol. 2011 Oct;13(10):1151-61
pubmed: 21856685
AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9
pubmed: 24136647
Neuro Oncol. 2018 May 18;20(6):848-857
pubmed: 29036412
J Neurooncol. 2012 Jul;108(3):491-8
pubmed: 22426926
Eur J Radiol. 2019 Nov;120:108642
pubmed: 31546124
Radiology. 2016 Aug;280(2):446-54
pubmed: 26919562
Neurosurgery. 2020 Oct 15;87(5):931-938
pubmed: 32365185
Med Phys. 2019 Dec;46(12):5677-5684
pubmed: 31580484
J Oncol Pharm Pract. 2018 Jan;24(1):33-36
pubmed: 27903792
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Front Oncol. 2019 May 21;9:374
pubmed: 31165039
Clin Cancer Res. 2016 Dec 1;22(23):5765-5771
pubmed: 27803067
J Clin Oncol. 2007 Sep 10;25(26):4104-9
pubmed: 17827460
Med Phys. 2015 Nov;42(11):6725-35
pubmed: 26520762
AJNR Am J Neuroradiol. 2019 Jun;40(6):928-934
pubmed: 31122918
J Magn Reson Imaging. 2009 May;29(5):1199-205
pubmed: 19388113
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
Sci Rep. 2021 Apr 7;11(1):7632
pubmed: 33828310
J Clin Oncol. 2009 Feb 10;27(5):740-5
pubmed: 19114704
Discov Med. 2015 Jun;19(107):471-7
pubmed: 26175405
Nat Clin Pract Oncol. 2008 Apr;5(4):220-33
pubmed: 18301415
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Neuro Oncol. 2014 Jul;16(7):984-90
pubmed: 24637230
Front Oncol. 2021 Apr 14;11:636672
pubmed: 33937035
Neuro Oncol. 2015 Aug;17(8):1051-63
pubmed: 25934816
Neurology. 2009 Apr 7;72(14):1217-22
pubmed: 19349600
Front Neurol. 2019 Mar 26;10:286
pubmed: 30984099
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
pubmed: 16611779
Radiology. 2009 Jul;252(1):182-9
pubmed: 19561256
Radiology. 2012 Sep;264(3):834-43
pubmed: 22771885
Neuroradiol J. 2006 Jun 30;19(3):322-9
pubmed: 24351217
Semin Ultrasound CT MR. 2021 Oct;42(5):490-506
pubmed: 34537117
Neuro Oncol. 2017 Nov 29;19(12):1688-1697
pubmed: 28499022
Neuroradiol J. 2021 Aug;34(4):355-362
pubmed: 33533273
Invest Radiol. 2017 Jun;52(6):360-366
pubmed: 28079702
Cancers (Basel). 2022 May 13;14(10):
pubmed: 35626018
Int Rev Neurobiol. 2020;151:281-297
pubmed: 32448612
AJNR Am J Neuroradiol. 2022 Feb;43(2):202-206
pubmed: 35058300
Radiol Med. 2022 Jul;127(7):803-808
pubmed: 35608757
Cancer J. 2012 Jan-Feb;18(1):45-50
pubmed: 22290257
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945